Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)

C Cordonnier, S Einarsdottir, S Cesaro… - The Lancet infectious …, 2019 - thelancet.com
Infection is a main concern after haemopoietic stem cell transplantation (HSCT) and a major
cause of transplant-related mortality. Some of these infections are preventable by …

Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis

MM Mehrabi Nejad, F Moosaie… - European journal of …, 2022 - Springer
Background Immunocompromised (IC) patients are at higher risk of severe SARS-CoV-2
infection, morbidity, and mortality compared to the general population. They should be …

Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era

ME Agha, M Blake, C Chilleo, A Wells… - Open forum infectious …, 2021 - academic.oup.com
We measured severe acute respiratory syndrome coronavirus 2 immunoglobulin G
responses in 67 patients with hematological malignancies after 2 messenger RNA vaccine …

[HTML][HTML] Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients

H Ali, D Ngo, A Aribi, S Arslan, S Dadwal… - … and cellular therapy, 2021 - Elsevier
The safety and efficacy of the severe acute respiratory syndrome coronavirus-2 (SARS-
CoV2) emergency-use authorized (EUA) vaccines have been confirmed in the general …

Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients

N Shem‐Tov, R Yerushalmi, I Danylesko… - British Journal of …, 2022 - Wiley Online Library
The immunogenicity and safety of Pfizer‐BioNTech BNT162b2 mRNA vaccine in allogeneic
haematopoietic stem cell transplantation (HSCT) recipients are unknown. We prospectively …

Influenza vaccines in immunosuppressed adults with cancer

R Bitterman, N Eliakim‐Raz, I Vinograd… - Cochrane Database …, 2018 - cochranelibrary.com
Objectives To assess the effectiveness of influenza vaccine in immunosuppressed adults
with malignancies. The primary review outcome is all‐cause mortality, preferably at the end …

Vaccine-preventable infections among solid organ transplant recipients in Switzerland

LN Walti, C Mugglin, M Mombelli, O Manuel… - JAMA Network …, 2023 - jamanetwork.com
Importance Vaccine responses are decreased in solid organ transplant (SOT) recipients,
and given the complexity of implementation, vaccination programs may be suboptimal. The …

[HTML][HTML] Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients

MU Mushtaq, M Shahzad, SG Chaudhary… - … and cellular therapy, 2021 - Elsevier
ABSTRACT Coronavirus disease 2019 (COVID-19), a respiratory illness caused by the
novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a …

Seasonal influenza vaccine in immunocompromised persons

M Bosaeed, D Kumar - Human vaccines & immunotherapeutics, 2018 - Taylor & Francis
Immunocompromised persons are at high risk of complications from influenza infection. This
population includes those with solid organ transplants, hematopoietic stem cell transplants …

[HTML][HTML] Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States

M Patel, J Chen, S Kim, S Garg, B Flannery… - Emerging Infectious …, 2020 - ncbi.nlm.nih.gov
Increasing use of immunosuppressive biologic therapies poses a challenge for infectious
diseases. Immunosuppressed patients have a high risk for influenza complications and an …